Itraconazole and Divarasib Interaction Study
Trial Summary
What is the purpose of this trial?
This is a Phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of Itraconazole on the pharmacokinetics (PK) and safety of Divarasib in healthy participants.
Research Team
Clinical Trials
Principal Investigator
Genentech, Inc.
Eligibility Criteria
This trial is for healthy individuals who can participate in a study to understand how Itraconazole affects the body's handling of another drug, Divarasib. Specific eligibility criteria are not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period A
Participants receive a single oral dose of Divarasib on Day 1
Treatment Period B
Participants receive Itraconazole BID on Day 1 and QD from Day 2 to Day 13, with Divarasib on Day 5
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Divarasib
- Itraconazole
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genentech, Inc.
Lead Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD